[go: up one dir, main page]

AR103832A1 - Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton - Google Patents

Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton

Info

Publication number
AR103832A1
AR103832A1 ARP160100550A ARP160100550A AR103832A1 AR 103832 A1 AR103832 A1 AR 103832A1 AR P160100550 A ARP160100550 A AR P160100550A AR P160100550 A ARP160100550 A AR P160100550A AR 103832 A1 AR103832 A1 AR 103832A1
Authority
AR
Argentina
Prior art keywords
inhibitor
pharmaceutical formulations
conditions
bruton
quinasa
Prior art date
Application number
ARP160100550A
Other languages
English (en)
Inventor
Atluri Harisha
Tan Heow
Kuehl Robert
Wah Chong Ching
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of AR103832A1 publication Critical patent/AR103832A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulaciones farmacéuticas del inhibidor de tirosina quinasa de Bruton (Btk) 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona. Métodos para usar el inhibidor de Btk, solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluido el linfoma, y enfermedades o condiciones inflamatorias. Reivindicación 52: Un proceso para preparar la formulación de comprimido sólido de alta carga de cualquiera de las reivindicaciones 1 a 49, caracterizado porque el proceso comprende un método de granulación húmeda.
ARP160100550A 2015-03-03 2016-03-02 Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton AR103832A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562127717P 2015-03-03 2015-03-03

Publications (1)

Publication Number Publication Date
AR103832A1 true AR103832A1 (es) 2017-06-07

Family

ID=59254075

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100550A AR103832A1 (es) 2015-03-03 2016-03-02 Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton

Country Status (2)

Country Link
AR (1) AR103832A1 (es)
MA (1) MA41643B1 (es)

Also Published As

Publication number Publication date
MA41643A (fr) 2018-01-09
MA41643B1 (fr) 2024-02-29

Similar Documents

Publication Publication Date Title
MX2017011270A (es) Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton.
DOP2022000096A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
MX372673B (es) Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
EA201591656A1 (ru) Комбинированная терапия с ибрутинибом
EA201690746A1 (ru) Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2017012430A (es) Formas solvatadas de un inhibidor de tirosina quinasa de bruton.
NZ728392A (en) High dosage strength tablets of rucaparib
UY37559A (es) Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
AR103832A1 (es) Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton
MX2019000159A (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa.
AR132685A2 (es) Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton
AR098210A1 (es) Combinaciones de inhibidores de la tirosina quinasa de bruton e inmunoterapias
TR201711933A2 (tr) Ti̇rozi̇n ki̇naz 2 (tyk2) enzi̇mi̇ni̇ selekti̇f i̇nhi̇be eden heterosi̇kli̇k bi̇leşi̇kler
TH168817A (th) อนุพันธ์อินโดลิซีนซึ่งเป็นสารยับยั้งฟอสโฟอิโนซิไทด์ 3-ไคเนส

Legal Events

Date Code Title Description
FC Refusal